Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lecia V Sequist

Showing results (11-20 of 272) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutationsTeresa Moran, Lecia V Sequist
The Oncologist|October 27, 2015
Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?Zofia Piotrowska, Lecia V Sequist
Seminars in Respiratory and Critical Care Medicine|July 30, 2005
Treatment of advanced non-small cell lung cancer in the elderlyLecia V Sequist, Panos Fidias
Radiology|November 7, 2023
Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a SprintLecia V Sequist, Coral Olazagasti
Current Treatment Options in Oncology|August 3, 2010
Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and HhJoel W Neal, Lecia V Sequist
Annual Review of Medicine|August 25, 2007
EGFR tyrosine kinase inhibitors in lung cancer: an evolving storyLecia V Sequist, Thomas J Lynch
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancerJoel W Neal, Lecia V Sequist
Biomarkers in Medicine|May 19, 2010
Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitorsNathan A Pennell, Lecia V Sequist
Nature Reviews. Clinical Oncology|February 2, 2010
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutationsJoel W Neal, Lecia V Sequist
Translational Lung Cancer Research|March 26, 2015
Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyondJoel W Neal, Lecia V Sequist
Pageof 28

Showing results (11-20 of 272) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutationsTeresa Moran, Lecia V Sequist
The Oncologist|October 27, 2015
Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?Zofia Piotrowska, Lecia V Sequist
Seminars in Respiratory and Critical Care Medicine|July 30, 2005
Treatment of advanced non-small cell lung cancer in the elderlyLecia V Sequist, Panos Fidias
Radiology|November 7, 2023
Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a SprintLecia V Sequist, Coral Olazagasti
Current Treatment Options in Oncology|August 3, 2010
Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and HhJoel W Neal, Lecia V Sequist
Annual Review of Medicine|August 25, 2007
EGFR tyrosine kinase inhibitors in lung cancer: an evolving storyLecia V Sequist, Thomas J Lynch
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancerJoel W Neal, Lecia V Sequist
Biomarkers in Medicine|May 19, 2010
Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitorsNathan A Pennell, Lecia V Sequist
Nature Reviews. Clinical Oncology|February 2, 2010
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutationsJoel W Neal, Lecia V Sequist
Translational Lung Cancer Research|March 26, 2015
Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyondJoel W Neal, Lecia V Sequist
Pageof 28